Innovation in the pharmaceutical sector is complex, costly, and highly regulated. To support innovative project leaders, startups, SMEs, manufacturers, and researchers, the European Medicines Agency (EMA) has established several scientific and regulatory support mechanisms.
Unlike other organizations, the EMA does not directly fund projects, but it plays a key role in securing and accelerating the development of drug innovations.
The EMA’s role in innovation
The EMA is responsible for the evaluation and supervision of medicines at the European level. Its objective is twofold:
- to guarantee the safety, quality, and efficacy of centrally authorized medicines,
- to promote rapid access to innovation, particularly when medical needs are not being met.
To this end, it offers tools that allow for early interaction with developers in order to anticipate regulatory challenges.
1. Innovation Task Force (ITF): The entry point for innovative projects
The Innovation Task Force (ITF) is a multidisciplinary group within the EMA that provides a platform for discussing the scientific, regulatory, and legal challenges of innovative medicines, such as advanced therapy medicinal products (ATMPs).
ITF guidance meetings allow developers, including academic researchers, European consortia, SMEs, or large companies, to engage in early and informal dialogue with the EMA. These free, online exchanges help clarify technical and scientific issues even before formal scientific advice is provided.
The ITF provides particular support to key areas of innovation, such as artificial intelligence, platform technologies, new methodological approaches, and the 3Rs principles for animal research. By facilitating these early exchanges, the ITF helps innovative projects reduce regulatory uncertainty and better plan their development.
2. The SME Office: Strategic Support for SMEs
The EMA’s SME Office supports small and medium-sized enterprises in the development and marketing of medicines within the European Union and the European Economic Area. To benefit from this support, companies must apply for SME status and meet the relevant European eligibility criteria.
Once SME status has been granted, companies can benefit from fee reductions or exemptions for regulatory procedures such as scientific advice, inspections and pharmacovigilance activities. SMEs also have access to additional practical services, including free-of-charge translation of product information into all EU languages for initial marketing authorisations, significantly easing administrative requirements.
In addition, SMEs are included in the EMA’s public SME register, which is designed to facilitate interactions, partnerships and collaborations with other stakeholders across the sector.
3. Scientific Advice and Protocol Assistance: securing the development strategy
EMA Scientific Advice helps developers ensure that their tests and studies are appropriate and well designed, thereby reducing the risk of major objections being raised during the evaluation of a marketing authorisation application. This approach also helps protect patients by avoiding participation in studies that would not generate meaningful or useful data.
Scientific advice is provided by the Committee for Medicinal Products for Human Use (CHMP), based on recommendations from the Scientific Advice Working Party (SAWP). For medicines intended to treat, prevent or diagnose diseases that pose a declared or potential public health risk, such as COVID-19 or avian influenza, the CHMP bases its advice on recommendations from the Emergency Task Force (ETF).
Protocol Assistance also covers aspects related to clinical trial applications, enabling developers to secure both regulatory and scientific elements before initiating clinical studies. In practice, this service reduces regulatory risk and facilitates development planning, particularly for innovative medicines or those addressing urgent public health needs.
4. Qualification of novel methodologies: recognising innovative approaches
The qualification of novel methodologies allows the EMA to assess and provide an official opinion on innovative methods or tools used in medicine development. This can include biomarkers, imaging methods, experimental models, or any scientific approach applied in non-clinical or clinical studies.
The process is overseen by the CHMP, which relies on recommendations from the Scientific Advice Working Party (SAWP). The evaluation is based on data submitted by the developer and often includes a public consultation with the scientific community, ensuring transparency and open discussion.
In some cases, before a methodology is fully qualified, the EMA may issue a letter of support. These letters summarise the methodology, its context of use, and the available data, and encourage data sharing and further studies to achieve formal qualification.
In summary, this process validates innovative methods before they are widely adopted, providing developers with regulatory recognition and greater scientific certainty for their projects.
5. Quality Innovation Group (QIG): supporting innovation from the manufacturing stage
The Quality Innovation Group (QIG) brings together experts in the quality of chemical and biological medicines, including advanced therapy medicinal products (ATMPs), as well as specialists in good manufacturing practice inspections. The group was established to assist developers from the earliest stages of a product’s lifecycle, facilitating discussions with various stakeholders: ad hoc experts, academics, European assessors and inspectors, international regulators, industry and academic associations, and through the EU Innovation Network.
The QIG supports the use of innovative methodologies in medicine development, such as new technologies, novel materials or devices, and the digitalisation of manufacturing processes. Its goal is to provide consistent guidance throughout the product development process, whether during formal regulatory procedures (scientific advice, protocol assistance, marketing authorisation applications, or post-authorisation procedures) or through informal meetings that help identify potential regulatory issues early on.
6. EU Innovation Network (EU‑IN): a collaborative platform for innovation
The EU Innovation Network (EU‑IN) is a working group aimed at strengthening collaboration between the EMA and national competent authorities on regulatory matters related to emerging therapies and technologies. The group also supports the development of innovative medicines and associated technologies. Its primary mission is to facilitate the development of these innovations by addressing gaps in early regulatory support, providing a platform for sharing best practices, and fostering direct engagement with innovators, thereby better supporting innovative projects across Europe.
7. PRIME: priority support for high-impact medicines
The benefits include:
- enhanced regulatory support,
- more frequent interactions with the EMA,
- the possibility of an accelerated assessment.
PRIME is particularly strategic for breakthrough innovations with high clinical impact.
The PRIME (PRIority MEdicines) programme is an EMA initiative designed to support the development of medicines that address unmet medical needs. It is a voluntary scheme based on early and enhanced dialogue with developers to optimise development plans and accelerate assessment, allowing patients to access promising treatments sooner.
Through PRIME, the EMA provides proactive support to ensure the generation of robust data on a medicine’s benefits and risks, and facilitates accelerated evaluation of marketing authorisation applications. The programme builds on the existing regulatory framework and tools, including scientific advice and accelerated assessment. Developers of medicines benefiting from PRIME can expect to be eligible for accelerated assessment at the time of their marketing authorisation application.
By engaging early with developers, the programme helps improve the quality of scientific evidence, ensuring that collected data are suitable for regulatory evaluation, while allowing patients to benefit sooner from therapies that may significantly improve their quality of life.
In summary
EMA’s innovation support is based on a key principle: better support for better innovation.
Even without direct funding, these mechanisms make it possible to :
- reduce regulatory risks,
- accelerate development,
- improve the chances of accessing the European market.
For any company or team developing an innovative medicine, engaging early with the EMA is a true strategic advantage. Atessia supports its clients throughout these processes, whether for ITF briefing meetings, the SME Office, Scientific Advice, or programmes such as PRIME, helping to secure and optimise the development of their innovative medicines.
Article written by Lamya SAOUSSEN, Junior Regulatory Affairs and External Communication Advisor
Sources :
SME : https://www.ema.europa.eu/en/about-us/support-smes
Scientific advice : https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-advice-protocol-assistance
EU-IN : https://www.ema.europa.eu/en/committees/working-parties-other-groups/eu-innovation-network-eu
PRIME : https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines